Celgene reportedly in talks to buy CAR-T cell therapy firm

17 January 2018

US biotech major Celgene (Nasdaq: CELG) is reportedly looking at what could be its second big acquisition for 2018, and is said to be discussions to purchase US CAR-T cell therapy company Juno Therapeutics (Nasdaq: JUNO) in order to bolster its blood cancer drugs portfolio.

The talks could produce a deal in the coming weeks, assuming they don’t fall apart, people familiar with the matter said, according to the Wall Street Journal. Terms of the possible deal couldn’t be learned. Juno had a market value of about $5.5 billion as of Tuesday afternoon.

The company had a market value of roughly $5.2 billion as of the close of regular trading on Tuesday, noted the WSJ. However, reacting to the current rumors, Juno’s shares leapt 44.74% to $45.60 after-hours.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK